Yongqiang Li

机构：Guangzhou First People's Hospital, Guangzhou Medical University · ORCID：0000-0002-8110-8835

发表论文 102 篇 · 总被引 1335 次 · h-index 19

代表论文

• Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma (2024 · Research · 被引 49)
• Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study (2025 · Cancer Cell · 被引 21)
• Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study. (2024 · Journal of Clinical Oncology · 被引 19)
• Mdivi1 ameliorates mitochondrial dysfunction in non‐alcoholic steatohepatitis by inhibiting JNK/MFF signaling (2023 · Journal of Gastroenterology and Hepatology · 被引 16)
• STIM1-regulated exosomal EBV-LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma (2023 · Cellular Oncology · 被引 13)
• Progress of research on molecular targeted therapies for colorectal cancer (2023 · Frontiers in Pharmacology · 被引 12)